FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Phase 2TerminatedNCT03042780

H. Lee Moffitt Cancer Center and Research Institute2 enrolled

Overview

The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas. This is a prospective Phase II open-label trial, stratifying gastroenteropancreatic high grade neuroendocrine carcinomas participants equally into two cohorts (first-line versus beyond first-line).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor Pancreatic Cancer Neuroendocrine Carcinomas of Pancreas Islet Cell Carcinoma

Interventions

FOLFIRINOXDRUG

The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.

Granulocyte colony-stimulating factor (G-CSF)DRUG

The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed neuroendocrine carcinoma of the gastrointestinal (GI) tract. Potential participants with unknown origin for the neuroendocrine carcinoma in which a gastroenteropancreatic origin is suspected (per pathologist or investigator discretion) will be eligible for the study. * Tumors must have a Ki-67 index greater than 20% and/or \>20 mitotic figures/10 high-power fields. * Must have metastatic disease. * Must measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. * Any line of treatment (first line versus beyond first line). * Age \>18 years. * Life expectancy of greater than 12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. * Must have adequate organ and marrow function. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Have had chemotherapy or radiotherapy within 3 weeks prior to entering the study. * Receiving any other investigational agents. * Untreated brain or meningeal metastases. * Prior treatment with 5-fluorouracil (5-FU), irinotecan or oxaliplatin. * Pre-treatment peripheral neuropathy greater than grade 1 per the CTCAE, version 4.0. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * A secondary primary cancer (excluding baso/squamous cell carcinoma of skin) within 1 year. * Active viral hepatitis or autoimmune hepatitis. The work-up to confirm active hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on investigator discretion. * Potential participants with childbearing potential who are not willing to use adequate contraception precautions during the study and for 3 months after stopping study chemotherapy.

Outcomes

Primary Outcomes

Objective Radiographic Response Rate (ORR)

The primary efficacy endpoint is objective response rate as determined by radiology review, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR): complete disappearance of all target lesions. Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameter. Progressive disease (PD): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). Stable Disease (SD): neither sufficient decrease to qualify for partial response nor sufficient increase to qualify for progressive disease.

Time frame: Up to 36 months

Secondary Outcomes

Progression Free Survival (PFS)

PFS: from initiation date of therapy to disease progression or death. Progressive disease (PD): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum).